Navigation Links
Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
Date:10/15/2010

rogression for Teriflunomide 14mg

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate (primary study endpoint) by 31% vs. placebo (p is less than or equal to 0.0005). The risk of disability progression (sustained for 12 weeks) was also significantly reduced by 30% for the 14mg dose (p=0.02) and numerically reduced by 24% for the 7mg dose (p=0.08). Both doses of teriflunomide were well tolerated with a similar number of patients reporting either treatment-emergent adverse events (TEAEs) including serious adverse events or TEAEs leading to treatment discontinuation in the treatment vs. placebo arms.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/players/English/46556-Sanofi-Aventis-Teriflunomide/

"We are very pleased with the successful results of the TEMSO study which are an important step forward in multiple sclerosis clinical research," said Marc Cluzel, M.D., Ph.D., Executive Vice President, Research & Development, sanofi-aventis. "These exciting results with teriflunomide represent a new real hope to delivering an oral therapy to patients who live with this serious condition and are eager for new treatment options, and more convenient product forms in-line with our sanofi-aventis commitment to multiple sclerosis."

The results of the TEMSO trial are the first study findings from a large phase III clinical development program on teriflunomide. These results were presented today during the European Committee for Treatment and Research in M
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Medisafe 1 Technologies Successfully Tests Prototype of Patented Syringe Locking Device
2. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
3. Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System
4. Omeros Successfully Unlocks Orphan GPCRs
5. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
6. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
7. MedAvante Opens Moscow Office and Successfully Completes First Centralized Ratings Assessment
8. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
9. Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc.
10. Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
11. Phonak Successfully Hosts Hearing Care for Adults 2009 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- Pomerantz LLP is investigating claims on behalf of investors ... VTAE ).  Such investors are advised to ... or 888-476-6529, ext. 237. The investigation ... directors have violated Sections 10(b) and 20(a) of the ... February 27, 2015, the Company announced that its partner ...
(Date:2/27/2015)... 2015 Securities lawyers at Dunnam & ... Ltd. (NASDAQ: SLXP ) in connection with ... investors are encouraged to contact attorney Hamilton Lindley by ... focuses upon the shareholder value of the transaction. Under ... only $158.00 per share in cash. At least one ...
(Date:2/27/2015)... 2015 Report Details   ... trends, R&D progress, and predicted revenues ,Where is the ... the commercial prospects for this market and related technologies? ... other trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... April 16, 2007 /PRNewswire-FirstCall/ --,Bionovo, Inc. will present ... agent BZL101, which is advancing to Phase 1/2,clinical ... American,Association of Cancer Research (AACR) being held at ... April 14 - 17, 2007. , Bionovo's poster ...
... Demonstrates Clinical Activity, a Novel Mechanism,of Action and ... HAVEN, Conn., April 16, 2007 /PRNewswire-FirstCall/ --,Achillion Pharmaceuticals, ... clinical antiviral activity of one of,Achillion's NS4A antagonists, ... infection at the 42nd Annual Meeting of the,European ...
Cached Medicine Technology:Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 2Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 2Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 4
(Date:3/1/2015)... York, NY (PRWEB) March 01, 2015 ... and seek insurance rates for term or universal policies ... of some of the best life insurance companies for ... through the system at http://quotespros.com/life-insurance.html . , The ... the search portal are tied to a number of ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Ticket Down is ... in Chicago at Soldier Field. Deadheads have been ... in January. , Grateful Dead was formed 50 years ago ... were together as one until the untimely death of Jerry ... combining different genres including blues, reggae, rock, bluegrass, folk, space ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 ERISAPros ... King and Carolyn Roddy to the professional staff of ... Compliance, graduated from The Ohio State University-Mortiz College of ... years of experience working with several Fortune 500 companies ... the area of corporate benefits. Her experiences range from ...
(Date:3/1/2015)... WA (PRWEB) February 28, 2015 CrossFit Attollo ... spring they are offering a special discount to new members. ... sign up for a three month contract will receive their ... month individually would cost members $440. The three month ... per month, and then the fourth month comes in at ...
(Date:2/28/2015)... March 01, 2015 Heart diseases are ... 10 percent of urban adult population and 5 percent ... heart diseases and 20-30 percent of them require specialized ... ailments and coronary vascular diseases (CVD). , A division ... new market research report titled “Indian Coronary Stent Market ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Companies for Single Adults Now Searchable at Insurance Website 2Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3
... , , SALEM, N.H., July ... President Tom Taylor to chair the trade organization,s Board of ... in developing and marketing disposable medical, diagnostic, and laboratory research ... recognized authority on practices and trends in the medical device ...
... fatal to chronic, researcher says , TUESDAY, July 14 ... mutated genes and gene processes that, together, contribute to ... tumor. , "There is not a single gene that ... Markus Bredel, co-author of two related papers in the ...
... , , URGES LEADERSHIP ON LUNG ... Today Lung Cancer Alliance praised President Obama,s nomination of Dr. Regina ... whose mother died of lung cancer, to change public awareness and public ... http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO ) , ...
... , , ATLANTA, July 14 ... and Medical Spa has earned the country,s first LEED certification for ... the nation,s healthiest and most energy efficient medical spa and venous ... Green Building Council (USGBC), the nation,s leading evaluator of environmentally sustainable ...
... , ... that the deaths could have been prevented, mourns highly experienced New York personal injury attorney, ... New York, ... on June 29, 2009 in a gruesome personal injury accident at a privately ...
... , SAN FRANCISCO, July 14 Burrill ... on its recently-completed divestment of three investigational compounds for dermatological ... agreement were not disclosed. , , ... inhibitor currently in Phase 2 development for the treatment of ...
Cached Medicine News:Health News:Roush Life Sciences' Taylor to Chair MassMEDIC 2Health News:Gene Connections Key to Brain Tumor Growth 2Health News:Gene Connections Key to Brain Tumor Growth 3Health News:LCA Congratulates Nominee For Surgeon General 2Health News:OH2 Medical Spa Achieves the First U.S. LEED(R) Certification for a Medical Commercial Interior 2Health News:Personal Injury Attorneys Contemplate Toxic Evidence in the Death of 3 Men in New York 2Health News:Personal Injury Attorneys Contemplate Toxic Evidence in the Death of 3 Men in New York 3Health News:Burrill Merchant Banking Advises Pfizer Inc. on Dermatology Portfolio Divestment 2
... full monochromatic and chromatic correction for the ... rich-contrast, completely flat images for observation and ... transmission of wavelengths up to the near ... of glass types of low autofluorescence makes ...
Inquire...
This is the most versatile family of objectives. One and the same set of objectives can be used for all common contrasting methods: Brightfield, darkfield, phase contrast, DIC, epi-fluorescence, and ...
... objectives have been completely redesigned by Nikon ... using a modulator inside the objective. That ... entire magnification range from 10x to 40x.,Apodized ... reduce halos in the image by reducing ...
Medicine Products: